Food and Drug Administration

FDA Approves New Indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients

WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic …

FDA Approves New Indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients Read More